Literature DB >> 24834370

The Sur1-Trpm4 Channel in Spinal Cord Injury.

J Marc Simard1, Seung Kyoon Woo2, Bizhan Aarabi2, Volodymyr Gerzanich2.   

Abstract

Spinal cord injury (SCI) is a major unsolved challenge in medicine. Impact trauma to the spinal cord shears blood vessels, causing an immediate 'primary hemorrhage'. During the hours following trauma, the region of hemorrhage enlarges progressively, with delayed or 'secondary hemorrhage' adding to the primary hemorrhage, and effectively doubling its volume. The process responsible for the secondary hemorrhage that results in early expansion of the hemorrhagic lesion is termed 'progressive hemorrhagic necrosis' (PHN). PHN is a dynamic process of auto destruction whose molecular underpinnings are only now beginning to be elucidated. PHN results from the delayed, progressive, catastrophic failure of the structural integrity of capillaries. The resulting 'capillary fragmentation' is a unique, pathognomonic feature of PHN. Recent work has implicated the Sur1-Trpm4 channel that is newly upregulated in penumbral microvessels as being required for the development of PHN. Targeting the Sur1-Trpm4 channel by gene deletion, gene suppression, or pharmacological inhibition of either of the two channel subunits, Sur1 or Trpm4, yields exactly the same effects histologically and functionally, and exactly the same unique, pathognomonic phenotype - the prevention of capillary fragmentation. The potential advantage of inhibiting Sur1-Trpm4 channels using glibenclamide is a highly promising strategy for ameliorating the devastating sequelae of spinal cord trauma in humans.

Entities:  

Keywords:  Glibenclamide; Riluzole; Spinal cord injury; Sur1-Trpm4 Channel

Year:  2013        PMID: 24834370      PMCID: PMC4019017          DOI: 10.4172/2165-7939.S4-002

Source DB:  PubMed          Journal:  J Spine        ISSN: 2165-7939


  69 in total

1.  Spatial and temporal evolution of hemorrhage in the hyperacute phase of experimental spinal cord injury: in vivo magnetic resonance imaging.

Authors:  M Bilgen; R Abbe; S J Liu; P A Narayana
Journal:  Magn Reson Med       Date:  2000-04       Impact factor: 4.668

2.  Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function.

Authors:  Y He; A Benz; T Fu; M Wang; D F Covey; C F Zorumski; S Mennerick
Journal:  Neuropharmacology       Date:  2002-02       Impact factor: 5.250

3.  Vascular mechanisms in the pathophysiology of human spinal cord injury.

Authors:  C H Tator; I Koyanagi
Journal:  J Neurosurg       Date:  1997-03       Impact factor: 5.115

4.  The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.

Authors:  F Duprat; F Lesage; A J Patel; M Fink; G Romey; M Lazdunski
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

5.  Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies.

Authors:  A Stefani; F Spadoni; G Bernardi
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

6.  2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.

Authors:  J Benavides; J C Camelin; N Mitrani; F Flamand; A Uzan; J J Legrand; C Gueremy; G Le Fur
Journal:  Neuropharmacology       Date:  1985-11       Impact factor: 5.250

7.  The unique histopathological responses of the injured spinal cord. Implications for neuroprotective therapy.

Authors:  L Guth; Z Zhang; O Steward
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

8.  A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury.

Authors:  Robert G Grossman; Michael G Fehlings; Ralph F Frankowski; Keith D Burau; Diana S L Chow; Charles Tator; Angela Teng; Elizabeth G Toups; James S Harrop; Bizhan Aarabi; Christopher I Shaffrey; Michele M Johnson; Susan J Harkema; Maxwell Boakye; James D Guest; Jefferson R Wilson
Journal:  J Neurotrauma       Date:  2013-10-11       Impact factor: 5.269

9.  Independent evaluation of the effects of glibenclamide on reducing progressive hemorrhagic necrosis after cervical spinal cord injury.

Authors:  Phillip G Popovich; Stanley Lemeshow; John C Gensel; C Amy Tovar
Journal:  Exp Neurol       Date:  2010-12-09       Impact factor: 5.330

10.  Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain.

Authors:  Mingkui Chen; Yafeng Dong; J Marc Simard
Journal:  J Neurosci       Date:  2003-09-17       Impact factor: 6.167

View more
  18 in total

Review 1.  Learning to promote recovery after spinal cord injury.

Authors:  James W Grau; Rachel E Baine; Paris A Bean; Jacob A Davis; Gizelle N Fauss; Melissa K Henwood; Kelsey E Hudson; David T Johnston; Megan M Tarbet; Misty M Strain
Journal:  Exp Neurol       Date:  2020-04-28       Impact factor: 5.330

2.  Pharmacological Transection of Brain-Spinal Cord Communication Blocks Pain-Induced Hemorrhage and Locomotor Deficits after Spinal Cord Injury in Rats.

Authors:  Jacob A Davis; Anne C Bopp; Melissa K Henwood; Rachel E Baine; Carol C Cox; James W Grau
Journal:  J Neurotrauma       Date:  2020-08-01       Impact factor: 5.269

3.  A brief period of moderate noxious stimulation induces hemorrhage and impairs locomotor recovery after spinal cord injury.

Authors:  Misty M Strain; Michelle A Hook; Joshua D Reynolds; Yung-Jen Huang; Melissa K Henwood; James W Grau
Journal:  Physiol Behav       Date:  2019-10-21

4.  Involvement of TRPM4 in detrusor overactivity following spinal cord transection in mice.

Authors:  F Aura Kullmann; Jonathan M Beckel; Bronagh McDonnell; Christian Gauthier; Andrew M Lynn; Amanda Wolf-Johnston; Anthony Kanai; Irina V Zabbarova; Youko Ikeda; William C de Groat; Lori A Birder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-27       Impact factor: 3.000

Review 5.  Sulfonylurea Receptor 1 in Central Nervous System Injury: An Updated Review.

Authors:  Ruchira M Jha; Anupama Rani; Shashvat M Desai; Sudhanshu Raikwar; Sandra Mihaljevic; Amanda Munoz-Casabella; Patrick M Kochanek; Joshua Catapano; Ethan Winkler; Giuseppe Citerio; J Claude Hemphill; W Taylor Kimberly; Raj Narayan; Juan Sahuquillo; Kevin N Sheth; J Marc Simard
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

6.  Hemorrhage and Locomotor Deficits Induced by Pain Input after Spinal Cord Injury Are Partially Mediated by Changes in Hemodynamics.

Authors:  Misty M Strain; David T Johnston; Rachel E Baine; Joshua A Reynolds; Yung-Jen Huang; Melissa K Henwood; Gizelle N Fauss; Jacob A Davis; Rajesh C Miranda; Christopher R West; James W Grau
Journal:  J Neurotrauma       Date:  2021-11-16       Impact factor: 5.269

7.  The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia.

Authors:  David B Kurland; Volodymyr Gerzanich; Jason K Karimy; Seung Kyoon Woo; Rudi Vennekens; Marc Freichel; Bernd Nilius; Joseph Bryan; J Marc Simard
Journal:  J Neuroinflammation       Date:  2016-06-01       Impact factor: 8.322

8.  A Direct Comparison of Three Clinically Relevant Treatments in a Rat Model of Cervical Spinal Cord Injury.

Authors:  Hillary Hosier; David Peterson; Orest Tsymbalyuk; Kaspar Keledjian; Bradley R Smith; Svetlana Ivanova; Volodymyr Gerzanich; Phillip G Popovich; J Marc Simard
Journal:  J Neurotrauma       Date:  2015-07-20       Impact factor: 5.269

9.  Glibenclamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.

Authors:  Ruchira M Jha; Stefania Mondello; Helen M Bramlett; C Edward Dixon; Deborah A Shear; W Dalton Dietrich; Kevin K W Wang; Zhihui Yang; Ronald L Hayes; Samuel M Poloyac; Philip E Empey; Audrey D Lafrenaye; Hong Q Yan; Shaun W Carlson; John T Povlishock; Janice S Gilsdorf; Patrick M Kochanek
Journal:  J Neurotrauma       Date:  2020-12-18       Impact factor: 5.269

10.  Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis.

Authors:  Tapas K Makar; Volodymyr Gerzanich; Vamshi K C Nimmagadda; Rupal Jain; Kristal Lam; Fahad Mubariz; David Trisler; Svetlana Ivanova; Seung Kyoon Woo; Min Seong Kwon; Joseph Bryan; Christopher T Bever; J Marc Simard
Journal:  J Neuroinflammation       Date:  2015-11-18       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.